MetaCap

BridgeBio Pharma (BBIO) vs Jazz Pharmaceuticals (JAZZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Jazz Pharmaceuticals (JAZZ) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 30.1% versus a gain of 11.6%. Over five years, BBIO leads with a +92.2% price change compared with +85.6% for JAZZ. BridgeBio Pharma is the larger company by market cap ($14.81 billion vs $14.78 billion), about 1.0 times the size.

Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -146.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBIO+11.63%JAZZ+30.14%
+51%+19%-12%
Nov 21, 20251 yearNov 20, 2026
BBIO+78.26%JAZZ+79.37%
+111%+8%-94%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBIO versus JAZZ key metrics
MetricBBIOJAZZ
Share price$76.03$230.26
Market cap$14.81B$14.78B
1-day change-2.75%-2.62%
YTD return-0.60%+35.45%
1-year return+11.63%+30.14%
5-year return+92.24%+85.56%
P/E ratio (TTM)—68.12
Forward P/E—8.61
EPS (TTM)$-3.03$3.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$502.08M$4.27B
Revenue growth (YoY)+126.26%+4.88%
Net income (latest FY)$-732.94M$-356.15M
Gross margin95.82%—
Operating margin-104.25%-10.08%
Net margin-145.98%-8.35%
52-week high$93.42$266.38
52-week low$62.50$156.95
Distance from 52-week high-18.61%-13.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+40.73%+29.20%
Average volume2.67M905.07K
Shares outstanding194.80M64.19M
Employees1,0812,890
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • JAZZ has outperformed BBIO by 18.5 percentage points over the past year.
  • Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
  • BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +4.88%).

About BridgeBio Pharma

BBIO stock →

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,081 employees

About Jazz Pharmaceuticals

JAZZ stock →

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees

BBIO vs JAZZ FAQ

Which is bigger, BridgeBio Pharma or Jazz Pharmaceuticals?

BridgeBio Pharma (BBIO) is larger, with a market capitalization of $14.81B compared with $14.78B for Jazz Pharmaceuticals (JAZZ).

Which stock has performed better over the past year, BBIO or JAZZ?

JAZZ returned +30.14% over the past 12 months, compared with +11.63% for BBIO (price return, excluding dividends). Past performance does not predict future results.

Are BridgeBio Pharma and Jazz Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons